Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$68.71
-0.4%
$69.07
$59.83
$87.77
$3.46B1.21377,535 shs54,891 shs
Indivior PLC stock logo
INDV
Indivior
$16.12
-0.2%
$13.39
$7.33
$16.33
N/A0.651.23 million shs365,333 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.59
+0.1%
$2.57
$1.05
$3.31
$550.60M0.972.94 million shs498,307 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$35.82
-0.1%
$33.61
$27.12
$60.90
$2.14B2.41964,087 shs120,400 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
+0.05%-2.98%-0.43%+4.14%-4.52%
Indivior PLC stock logo
INDV
Indivior
+3.59%+5.14%+17.36%+79.36%+50.05%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
+1.97%+1.57%+1.57%+108.87%+13.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.29%-6.81%+5.69%-2.58%-36.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
2.4696 of 5 stars
2.33.00.00.02.13.31.3
Indivior PLC stock logo
INDV
Indivior
1.4849 of 5 stars
1.61.00.00.03.31.71.9
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
4.041 of 5 stars
4.55.00.00.02.53.30.0
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.3152 of 5 stars
3.45.00.04.42.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
2.67
Moderate Buy$80.3316.93% Upside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$17.005.46% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$8.17214.95% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4040.72% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, TWST, and INDV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
7/1/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/30/2025
Indivior PLC stock logo
INDV
Indivior
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
6/23/2025
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$82.00 ➝ $76.00
6/10/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/3/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $11.00
6/2/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $8.00
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $6.00
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $9.00
5/23/2025
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $85.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$1.75B1.98$9.66 per share7.11$56.65 per share1.21
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.88 per share8.57($2.52) per shareN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$8.33M66.82N/AN/A$0.35 per share7.41
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.86N/AN/A$8.07 per share4.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$200.55M$5.2113.1874.68N/A14.27%10.21%3.08%N/A
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A9.43N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)

Latest TSHA, HHH, TWST, and INDV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.07N/AN/AN/A$1.61 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
7/24/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.25N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million
5/7/2025Q1 2025
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$0.13$0.21+$0.08$0.21$187.43 million$199.33 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
1.84
1.41
1.41
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.77
5.35
5.35
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
93.83%
Indivior PLC stock logo
INDV
Indivior
60.33%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
33.00%
Indivior PLC stock logo
INDV
Indivior
N/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.78%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
60850.39 million33.76 millionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
180214.66 million206.55 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

Twist Bioscience: Still Not There Yet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Howard Hughes stock logo

Howard Hughes NYSE:HHH

$68.70 -0.27 (-0.38%)
As of 11:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Indivior stock logo

Indivior NASDAQ:INDV

$16.12 -0.04 (-0.25%)
As of 11:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$2.59 +0.00 (+0.12%)
As of 11:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$35.82 -0.04 (-0.10%)
As of 11:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.